Allergy Care

Global Allergy Care Market to Reach US$33.1 Billion by 2030

The global market for Allergy Care estimated at US$22.9 Billion in the year 2024, is expected to reach US$33.1 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Eye Allergy Type, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$8.2 Billion by the end of the analysis period. Growth in the Rhinitis Type segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.2 Billion While China is Forecast to Grow at 9.8% CAGR

The Allergy Care market in the U.S. is estimated at US$6.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.7 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Allergy Care Market – Key Trends & Drivers Summarized

Why Is Allergy Care Becoming a Central Focus in Global Health Management?

Allergy care is rapidly becoming a critical component of modern healthcare as allergy-related conditions surge across all age groups and geographies. Factors such as increased urbanization, environmental pollution, climate change, and altered dietary patterns have collectively contributed to a higher prevalence of allergic diseases, including asthma, allergic rhinitis, eczema, and food allergies. These conditions, though often considered manageable, can significantly impair quality of life, productivity, and long-term health when left unaddressed. Growing awareness among patients and healthcare providers has shifted allergy management from a reactive to a proactive model, where early diagnosis and consistent treatment are emphasized. The chronic nature of many allergic conditions means that patients often require long-term, sometimes lifelong, care plans, making the demand for reliable, accessible allergy treatment more urgent than ever. Furthermore, the impact of allergies is not confined to individuals—there are broader public health implications, particularly when allergies exacerbate other medical conditions or result in emergency care. Schools, workplaces, and travel sectors are increasingly adopting allergy-friendly policies in recognition of how widespread and disruptive these issues can be. As the understanding of immunological responses deepens, allergy care is becoming more personalized, evidence-based, and embedded in broader chronic disease strategies. The shift toward integrated care models ensures that allergy treatment is no longer seen in isolation but as a vital aspect of preventive and community healthcare.

How Are Advances in Diagnostics and Therapies Transforming Allergy Management?

Technological and medical advances are revolutionizing how allergies are diagnosed, treated, and monitored, leading to a more efficient and individualized approach to care. Traditional skin-prick and blood-based allergy tests are now being complemented—and in some cases, replaced—by highly specific molecular diagnostics that can identify precise allergen components, improving diagnostic accuracy and tailoring treatment. This precision helps distinguish between true allergies and sensitivities, reducing misdiagnosis and inappropriate interventions. In terms of therapeutics, allergen-specific immunotherapy (AIT), delivered through subcutaneous injections or sublingual tablets, has gained traction for its disease-modifying potential, offering long-term relief and even remission in some patients. Biologic therapies, including monoclonal antibodies such as omalizumab and dupilumab, have opened new avenues for patients with severe or treatment-resistant allergies, particularly those with overlapping conditions like asthma or chronic urticaria. At the same time, the development of mobile health tools, wearable monitors, and connected inhalers are enabling patients and caregivers to track symptoms, manage medications, and anticipate flare-ups through real-time analytics. Telehealth platforms have made specialist consultations more accessible, especially in underserved or rural areas. Dietary management tools for food allergies and innovations in hypoallergenic product development further enhance the safety and autonomy of allergic individuals. These technological shifts are not only enhancing the efficacy of allergy care but also making it more patient-centered and aligned with the digital transformation of healthcare systems globally.

What Social and Environmental Factors Are Shaping Allergy Care Demand Across Regions?

The increasing global demand for allergy care is deeply influenced by socio-environmental dynamics that differ across regions but contribute uniformly to the allergy burden. Urban populations, particularly in fast-growing cities across Asia, Africa, and South America, are experiencing rising exposure to air pollutants, industrial chemicals, and urban allergens such as dust mites and mold spores—factors strongly associated with the onset of allergic conditions. Climate change is also playing a pivotal role by extending pollen seasons and altering the distribution of allergenic plants, thereby exposing populations to longer and more intense allergen exposure. In more industrialized nations, the “hygiene hypothesis” has gained renewed attention, suggesting that reduced exposure to microbes during early childhood may predispose individuals to allergies. Lifestyle changes, including altered diets, increased time indoors, and overuse of antibiotics, further contribute to shifts in the immune system that can trigger allergic responses. Moreover, rising awareness of allergies, driven by public education campaigns and celebrity advocacy, has led to a surge in self-diagnosis and over-the-counter treatment demand, even in populations previously underserved. Educational institutions, airlines, and food manufacturers are adapting their practices to accommodate individuals with severe allergies, further illustrating the social footprint of allergy care. These global and regional dynamics are not only increasing the volume of allergy-related cases but also driving the need for culturally sensitive, climate-adapted, and demographically appropriate care solutions that can meet diverse population needs.

What Are the Core Drivers Fueling Growth in the Global Allergy Care Market?

The growth of the global allergy care market is driven by a confluence of medical, demographic, technological, and economic factors. First and foremost, the steadily rising incidence of allergic diseases—spanning respiratory, skin, food, and insect-based allergies—is creating a consistent and expanding patient population that requires long-term management. With healthcare systems increasingly shifting toward chronic disease prevention and management, allergies have been recognized as both a clinical priority and a public health challenge. Secondly, advancements in biotechnology and pharmaceuticals are generating innovative treatment modalities that attract investment and enhance care quality. The growing availability of biologics, personalized immunotherapy, and rapid diagnostic tools is broadening the range of treatable allergy profiles, especially for patients with complex or multi-system allergic conditions. Economic factors such as rising disposable incomes in emerging markets are allowing more people to access allergy diagnostics and treatment services, creating fertile ground for market expansion. Healthcare infrastructure improvements and government reimbursement policies in regions like Europe and North America are making allergy care more accessible and standardized. Simultaneously, consumer-driven demand for allergen-free foods, cosmetics, and household products is stimulating growth in the adjacent allergy-conscious product markets. Digital health adoption is also enabling better symptom tracking, medication adherence, and virtual consultations, thus improving disease management and patient satisfaction. These combined drivers are setting the stage for robust and sustained growth in the allergy care market, positioning it as a crucial sector in the future of global health.

SCOPE OF STUDY:

The report analyzes the Allergy Care market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Eye Allergy Type, Rhinitis Type, Asthma Type, Skin Allergy Type, Food Allergies Type, Other Allergy Types); Treatment (Anti-Allergy Drugs Treatment, Immunotherapy Treatment); Distribution Channel (Hospital Distribution Channel, Online Distribution Channel, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• AbbVie Inc.
• Akorn, Inc.
• ALK-Abelló A/S
• Almirall, S.A.
• Allergy Therapeutics plc
• Allergopharma GmbH & Co. KG
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• DBV Technologies S.A.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• HAL Allergy Group
• Johnson & Johnson
• Leti Pharma S.L.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more